New hope for tough esophageal cancers: triple therapy shows promise

This study is for people with esophageal cancer that did not shrink after initial treatment. It tests whether adding low-dose radiation to a combination of immunotherapy (toripalimab) and chemotherapy can improve outcomes. Participants will receive the treatment before surgery, and those who still have cancer after surgery will continue immunotherapy for up to a year. The goal is to see if this approach can reduce or eliminate the tumor before surgery.